Key features and details
- Goat polyclonal to TRC8 - C-terminal
- Suitable for: WB, IHC-P
- Reacts with: Human
- Isotype: IgG
Product nameAnti-TRC8 antibody - C-terminal
DescriptionGoat polyclonal to TRC8 - C-terminal
Tested applicationsSuitable for: WB, IHC-Pmore details
Species reactivityReacts with: Human
Predicted to work with: Rabbit, Monkey, Gorilla, Orangutan
- Human placenta tissue; Human skeletal muscle lysate.
This product was previously labelled as RNF139
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.30
Preservative: 0.02% Sodium azide
Constituents: 0.5% BSA, 99% Tris buffered saline
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab189173 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 0.5 - 1.5 µg/ml. Predicted molecular weight: 76 kDa.|
|IHC-P||Use a concentration of 3.75 µg/ml. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.|
RelevanceRNF139 is a multi-membrane spanning protein E3 ubiquitin ligase which is mutated in clear-cell renal carcinomas. It contains a sterol-sensing domain and a RING-H2 motif essential for ubiquitin ligase activity. It is a potential tumor suppressor for renal cell carcinoma. Human kidney cells are growth inhibited by RNF139. Inhibition is manifested by G2/M arrest and is dependent upon the ubiquitin ligase activity of the RING domain. Expression of RNF139 represses genes involved in cholesterol and fatty acid biosynthesis that are transcriptionally regulated by the sterol response element binding proteins (SREBPs). RNF139 modulation of SREBP activity comprises a novel regulatory link between growth control and the cholesterol/lipid homeostasis pathway.
Cellular localizationEndoplasmic reticulum membrane; Multi-pass membrane protein.
- E3 ubiquitin-protein ligase RNF139 antibody
- HRCA1 antibody
- RCA1 antibody
Anti-TRC8 antibody - C-terminal (ab189173) at 0.5 µg/ml + Human skeletal muscle cell lysate in RIPA buffer at 35 µg/ml
Developed using the ECL technique.
Predicted band size: 76 kDa
Exposure time: 1 hour
Immunohistochemistry analysis of Formalin-fixed, paraffin-embedded Human placenta tissue labeling TRC8 with ab189173 at 3.75µg/ml.
ab189173 has not yet been referenced specifically in any publications.